In this article, we will discuss Enasidenib (Dosage Overview). So, let’s get started.
Acute Myeloid Leukemia
Enasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Select patients for the treatment of AML with enasidenib based on the presence of IDH2 mutations in the blood or bone marrow.
The recommended starting dose of enasidenib is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
Do not split or crush enasidenib tablets. Administer enasidenib tablets orally about the same time each day.
If a dose of enasidenib is vomited, missed, or not taken at the usual time, administer the dose as soon as possible on the same day, and return to the normal schedule the following day.